[ ARMO Biosciences raises $67M in Series C ]

ARMO Biosciences has raised $67 million in Series C funding.

Founded in 2013, ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics.

The Series C-1 proceeds will be used to initiate phase 2/3 studies with ARMO’s lead immunotherapy agent AM0010 in non-small cell lung cancer and renal cell cancer and to support an ongoing pivotal phase 3 clinical trial in advanced pancreatic cancer. The proceeds will also support the further development of ARMO’s pipeline of additional immunotherapy product candidates that include monoclonal antibodies directed against checkpoint inhibitors.

Funding  Series C
Founded  2013
Country  USA
City  Redwood City, California
Founder / CEO  Peter Van Vlasselaer
Deal Size  $67M
Investors  Clough Capital Partners
 Qiming Venture Partners
 Decheng Capital
 Sequoia Capital
 Quan Capital
 RTW Investments LLC
 Kleiner Perkins Caufield & Byers
 OrbiMed
 DAG Ventures
 NanoDimension
 HBM Healthcare Investments AG
 GV
 Celgene
Previous Investors  Kleiner Perkins Caufield & Byers
 OrbiMed
 GV
 NanoDimension
 DAG Ventures
 HBM Healthcare Investments AG



Author:
Investor & Serial Startupper ;-))

Leave a Reply

Registrations
Password must be at least 7 characters long.
Please login to view this page.
Please login to view this page.
Please login to view this page.